HomeCompareARGNF vs ADC

ARGNF vs ADC: Dividend Comparison 2026

ARGNF yields 0.25% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADC wins by $158.9K in total portfolio value
10 years
ARGNF
ARGNF
● Live price
0.25%
Share price
$814.94
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$24.94
Full ARGNF calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — ARGNF vs ADC

📍 ADC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARGNFADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARGNF + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ARGNF pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARGNF
Annual income on $10K today (after 15% tax)
$20.86/yr
After 10yr DRIP, annual income (after tax)
$21.20/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, ADC beats the other by $68,656.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARGNF + ADC for your $10,000?

ARGNF: 50%ADC: 50%
100% ADC50/50100% ARGNF
Portfolio after 10yr
$99.5K
Annual income
$40,411.12/yr
Blended yield
40.62%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

ARGNF
Analyst Ratings
1
Strong
20
Buy
3
Hold
Consensus: Buy
Altman Z
24.1
Piotroski
5/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARGNF buys
0
ADC buys
0
No recent congressional trades found for ARGNF or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARGNFADC
Forward yield0.25%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$20.0K$178.9K
Annual income after 10y$24.94$80,797.29
Total dividends collected$248.00$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: ARGNF vs ADC ($10,000, DRIP)

YearARGNF PortfolioARGNF Income/yrADC PortfolioADC Income/yrGap
1← crossover$10,725$24.54$10,990$580.36$265.00ADC
2$11,500$24.60$12,301$860.26$801.00ADC
3$12,329$24.65$14,104$1,298.62$1.8KADC
4$13,217$24.70$16,691$2,008.16$3.5KADC
5$14,167$24.75$20,580$3,205.09$6.4KADC
6$15,184$24.79$26,754$5,330.02$11.6KADC
7$16,271$24.83$37,196$9,345.14$20.9KADC
8$17,435$24.87$56,244$17,523.09$38.8KADC
9$18,681$24.90$94,286$35,736.21$75.6KADC
10$20,013$24.94$178,949$80,797.29$158.9KADC

ARGNF vs ADC: Complete Analysis 2026

ARGNFStock

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

Full ARGNF Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this ARGNF vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARGNF vs SCHDARGNF vs JEPIARGNF vs OARGNF vs KOARGNF vs MAINARGNF vs NNNARGNF vs EPRTARGNF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.